Nrf2 Enhances Resistance of Cancer Cells to Chemotherapeutic Drugs, the Dark Side of Nrf2

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2008 Apr 17

PMID 18413364

Citations 428

Authors

Xiao-Jun Wang

Zheng Sun

Nicole F Villeneuve

Shirley Zhang

Fei Zhao

Yanjie Li

Weimin Chen

Xiaofang Yi

Wenxin Zheng

Georg T Wondrak

Pak Kin Wong

Donna D Zhang

Affiliations

Soon will be listed here.

Abstract

Drug resistance during chemotherapy is the major obstacle to the successful treatment of many cancers. Here, we report that inhibition of NF-E2-related factor 2 (Nrf2) may be a promising strategy to combat chemoresistance. Nrf2 is a critical transcription factor regulating a cellular protective response that defends cells against toxic insults from a broad spectrum of chemicals. Under normal conditions, the low constitutive amount of Nrf2 protein is maintained by the Kelch-like ECH-associated protein1 (Keap1)-mediated ubiquitination and proteasomal degradation system. Upon activation, this Keap1-dependent Nrf2 degradation mechanism is quickly inactivated, resulting in accumulation and activation of the antioxidant response element (ARE)-dependent cytoprotective genes. Since its discovery, Nrf2 has been viewed as a 'good' transcription factor that protects us from many diseases. In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide. Inversely, downregulation of the Nrf2-dependent response by overexpression of Keap1 or transient transfection of Nrf2-small interfering RNA (siRNA) rendered cancer cells more susceptible to these drugs. Upregulation of Nrf2 by the small chemical tert-butylhydroquinone (tBHQ) also enhanced the resistance of cancer cells, indicating the feasibility of using small chemical inhibitors of Nrf2 as adjuvants to chemotherapy to increase the efficacy of chemotherapeutic agents. Furthermore, we provide evidence that the strategy of using Nrf2 inhibitors to increase efficacy of chemotherapeutic agents is not limited to certain cancer types or anticancer drugs and thus can be applied during the course of chemotherapy to treat many cancer types.

Citing Articles

Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.

KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.

Oskomic M, Tomic A, Barbaric L, Matic A, Kindl D, Matovina M Cancers (Basel). 2025; 17(3).

PMID: 39941813 PMC: 11816071. DOI: 10.3390/cancers17030447.

Tanshinlactone triggers methuosis in breast cancer cells via NRF2 activation.

Lin W, Huang Z, Zhang X, Zheng D, Yang Y, Shi M Front Pharmacol. 2025; 15:1534217.

PMID: 39906392 PMC: 11790599. DOI: 10.3389/fphar.2024.1534217.

Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome It.

Mendoza E, Ciriolo M, Ciccarone F Antioxidants (Basel). 2025; 14(1).

PMID: 39857427 PMC: 11762716. DOI: 10.3390/antiox14010094.

and hybrid approach to unveil triterpenoids from leaves as potential compounds for inhibiting Nrf2.

Nguyen M, Le N, Nguyen B, Nguyen M, Van Do T, Le T RSC Adv. 2025; 15(3):1915-1923.

PMID: 39839230 PMC: 11749225. DOI: 10.1039/d4ra07646j.

References

Zhang D . Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 2006; 38(4):769-89. DOI: 10.1080/03602530600971974. View

Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K . Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004; 64(18):6424-31. DOI: 10.1158/0008-5472.CAN-04-1906. View

Chan J, Kwong M . Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta. 2000; 1517(1):19-26. DOI: 10.1016/s0167-4781(00)00238-4. View

Suh J, Shenvi S, Dixon B, Liu H, Jaiswal A, Liu R . Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A. 2004; 101(10):3381-6. PMC: 373470. DOI: 10.1073/pnas.0400282101. View

Padmanabhan B, Tong K, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M . Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 2006; 21(5):689-700. DOI: 10.1016/j.molcel.2006.01.013. View

Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, OConnor T . High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci. 2001; 59(1):169-77. DOI: 10.1093/toxsci/59.1.169. View

Xue C, Haber M, Flemming C, Marshall G, Lock R, Mackenzie K . p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 2007; 67(21):10351-60. DOI: 10.1158/0008-5472.CAN-06-4345. View

Hu X, Roberts J, Apopa P, Kan Y, Ma Q . Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. Mol Cell Biol. 2006; 26(3):940-54. PMC: 1347017. DOI: 10.1128/MCB.26.3.940-954.2006. View

Swift L, Rephaeli A, Nudelman A, Phillips D, Cutts S . Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006; 66(9):4863-71. DOI: 10.1158/0008-5472.CAN-05-3410. View

10.

Rangasamy T, Guo J, Mitzner W, Roman J, Singh A, Fryer A . Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med. 2005; 202(1):47-59. PMC: 2212893. DOI: 10.1084/jem.20050538. View

11.

Ramos-Gomez M, Kwak M, Dolan P, Itoh K, Yamamoto M, Talalay P . Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(6):3410-5. PMC: 30667. DOI: 10.1073/pnas.051618798. View

12.

Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M . Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol. 2001; 173(3):154-60. DOI: 10.1006/taap.2001.9176. View

13.

Tew K . Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54(16):4313-20. View

14.

Yates M, Kensler T . Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect. 2007; 20(2):109-17. DOI: 10.1358/dnp.2007.20.2.108343. View

15.

Kim Y, Yamaguchi Y, Kondo N, Masutani H, Yodoi J . Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene. 2003; 22(12):1860-5. DOI: 10.1038/sj.onc.1206369. View

16.

Kobayashi A, Kang M, Okawa H, Ohtsuji M, Zenke Y, Chiba T . Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24(16):7130-9. PMC: 479737. DOI: 10.1128/MCB.24.16.7130-7139.2004. View

17.

Zhang D, Lo S, Cross J, Templeton D, Hannink M . Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004; 24(24):10941-53. PMC: 533977. DOI: 10.1128/MCB.24.24.10941-10953.2004. View

18.

Jozkowicz A, Was H, Dulak J . Heme oxygenase-1 in tumors: is it a false friend?. Antioxid Redox Signal. 2007; 9(12):2099-117. PMC: 2096718. DOI: 10.1089/ars.2007.1659. View

19.

Loboda A, Was H, Jozkowicz A, Dulak J . Janus face of Nrf2-HO-1 axis in cancer--friend in chemoprevention, foe in anticancer therapy. Lung Cancer. 2007; 60(1):1-3. DOI: 10.1016/j.lungcan.2007.10.024. View

20.

Stacy D, Ely K, Massion P, Yarbrough W, Hallahan D, Sekhar K . Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 2006; 28(9):813-8. DOI: 10.1002/hed.20430. View